+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07187063

Evaluating Urine Tumor DNA Using the UroAmp Test to Reduce Cystoscopy Frequency for High-Risk Non-Muscle Invasive Bladder Cancer

Led by Lahey Clinic · Updated on 2026-11-03

56

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of urine tumor DNA utDNA as a marker for non-muscle invasive bladder cancer NMIBC to identify patients who might benefit from less frequent cystoscopy surveillance. This diagnostic trial aims to improve monitoring methods for those with high-risk bladder cancer by comparing standard care with a de-intensified surveillance approach. Participants are randomly assigned to one of two groups a de-intensified surveillance group that undergoes fewer cystoscopy procedures guided by the UroAmp Test, a non-invasive genomic urine test, or a standard surveillance group receiving regular follow-ups and standard care. The UroAmp Test detects and monitors urothelial cancer risk potentially earlier than traditional methods, helping to tailor surveillance frequency. During the study, participants will be monitored for up to 24 months with assessments including the number of cystoscopies performed, event-free survival, recurrence-free survival, and patient-reported outcomes. The study will track these measures to evaluate how well urine tumor DNA can guide surveillance intensity. Safety and overall health will be observed throughout the trial period.

CONDITIONS

Brief Title

Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer

Research Team

L

Linda Topjian

C

Colette Osborne

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here